Inhibitors of bruton's tyrosine kinase
BNRE20220005BUndetermined Publication Date: 2022-10-31PHARMACYCLICS LLC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- BNRE20220005
- Authority / Receiving Office
- BN · BN
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2006-10-06
- Filing Date
- 2022-07-07
- Publication Date
- 2022-10-31
- Estimated Expiration
- 2042-07-07
Abstract
Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Need to check novelty before this filing date? Find Prior Art